Recent Updates
Recently added Catalysts

PRO 2000

Phase 1

HIV Infections | Small molecule | Infectious Disease |PROCEPT BioRobotics Corporation|Last Updated: Jul 30, 2008

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment60
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00006207Safety and Tolerability of the Vaginal Gel PRO 2000/5PHASE1 COMPLETED 60 - -Jul 30, 20081 United States
Unlock Drug Trial Details
Study Design & Arms
PurposePREVENTION
Interventions
NameTypeDescription
PRO 2000DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexFEMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria Volunteers may be eligible for this study if they: * Are female and 18-45 years of age. * Are willing and able to complete daily study records. * Are willing to undergo clinical exams and testing. * Either have regular menstrual periods or do not menstruate due to use of hormone...

Countries:United States
Unlock Eligibility Criteria